Vaxcyte (PCVX) Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has reported Non-Current Assets for 8 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 7.63% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 7.63% YoY), while the FY2025 annual figure was $1.4 billion, down 20.19% from the prior year.
• Non-Current Assets rose to $1.5 billion in Q1 2026 per PCVX's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.7 billion in Q4 2024 and bottomed at $42.3 million in Q3 2022.
• Historically, Non-Current Assets has averaged $758.9 million across 5 years, with a median of $574.2 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Assets surged 570.85% — and 2025, when it retreated 20.19%.
• Vaxcyte's Non-Current Assets stood at $63.6 million in 2022, then jumped by 390.33% to $312.0 million in 2023, then surged by 452.42% to $1.7 billion in 2024, then declined by 20.19% to $1.4 billion in 2025, then climbed by 11.59% to $1.5 billion in 2026.
• Business Quant data shows PCVX's Non-Current Assets at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.